United States

Veloxis Pharmaceuticals A/S (VELOX.CO)

VELOX.CO on Copenhagen Stock Exchange

4:01am EDT
Change (% chg)

kr.-0.01 (-0.70%)
Prev Close
Day's High
Day's Low
Avg. Vol
52-wk High
52-wk Low

Latest Key Developments (Source: Significant Developments)

Veloxis Pharmaceuticals raises DKK 4.1 mln from exercise of warrants
Monday, 13 Jun 2016 02:00am EDT 

Veloxis Pharmaceuticals A/S : Capital increase from exercise of warrants amounts to 4.1 million Danish crowns ($620,977) .About 11.7 million new shares were subscribed for at 0.35 crown per share (6.9 million shares) and 0.36 crown per share (4.8 million shares).  Full Article

Veloxis Pharmaceuticals Q1 operating loss at $6.9 mln
Thursday, 19 May 2016 03:35am EDT 

Veloxis Pharmaceuticals A/S : Said on Wednesday Q1 revenue $1.5 million versus $647,000 year ago . Q1 operating loss $6.9 million versus loss $7.0 million year ago . Q1 pre-tax loss $7.1 million versus loss $4.3 million year ago .Maintains its 2016 outlook of an operating and net loss of 120 million – 160 million Danish crowns ($17.6–23.4 million based on an assumed average exchange rate of 1 $= 6.83 Danish crown).  Full Article

Veloxis Pharmaceuticals appoints Michael Thomas Heffernan new chairman
Wednesday, 6 Apr 2016 09:05am EDT 

Veloxis Pharmaceuticals A/S:Board of directors constituted itself with Michael Thomas Heffernan as chairman of board.  Full Article

Veloxis Pharmaceuticals: Johnny Stilou to step down as EVP & CFO
Wednesday, 6 Apr 2016 05:28am EDT 

Veloxis Pharmaceuticals A/S:Johnny Stilou will step down as EVP & Chief Financial Officer as part of the Company’s decision to close down all Danish activities and move to the U.S.Johnny Stilou will remain with company until end of August 2016 to secure transition of activities to U.S.  Full Article

Veloxis Pharmaceuticals issues FY 2016 guidance
Wednesday, 9 Mar 2016 07:30am EST 

Veloxis Pharmaceuticals A/S:‍Expects an operating loss in FY 2016 of 120 million - 160 million Danish crowns compared to realized operating loss of 197 million crowns in FY 2015​.‍Net loss in FY 2016 is expected to be in range of 120 million - 160 million crowns compared to net loss of 176 million crowns in FY 2015​.  Full Article

Veloxis Pharmaceuticals moves Danish activities to U.S.
Wednesday, 9 Mar 2016 02:36am EST 

Veloxis Pharmaceuticals A/S:Says has decided to close its office in Hørsholm, Denmark, and move all activities to the U.S. where most of the company’s current activities is already located.The process is expected to be completed during H2 2016.  Full Article

Veloxis Announces Change In Management
Thursday, 10 Dec 2015 04:32pm EST 

Veloxis Pharmaceuticals A/S:William J. Polvino steps down as President and CEO after more than six years in the role.Polvino will be followed by Craig A. Collard who will take over the position as President and CEO with immediate effect.  Full Article

Veloxis launches Envarsus XR for kidney transplant patients in US
Monday, 7 Dec 2015 02:30am EST 

Veloxis Pharmaceuticals A/S:Launches Envarsus XR for treatment of kidney transplant patients in U.S.Will be marketing and selling Envarsus XR through its own dedicated specialty sales force in the U.S.  Full Article

Veloxis Pharmaceuticals keeps FY 2015 outlook
Thursday, 12 Nov 2015 01:30am EST 

Veloxis Pharmaceuticals A/S:Still expects FY 2015 operating loss in the range of 175 million - 205 million Danish crowns.Still expects FY 2015 net loss in the range of 155 million - 185 million crowns.FY 2015 EBIT loss of 196.00 million crowns and net loss of 173.50 million crowns - Thomson Reuters I/B/E/S.  Full Article

Veloxis Pharmaceuticals A/S establishes sponsored Level 1 ADR program in U.S.
Wednesday, 14 Oct 2015 02:50am EDT 

Veloxis Pharmaceuticals A/S:Establishes sponsored Level 1 American depositary receipt (ADR) program in the U.S.Will enable U.S. investors to trade in ADRs denominated in U.S. dollars.Says each ADR represents 100 ordinary shares and will trade on U.S. over-the-Counter (OTC) market.Says ADR program will not be accompanied by issuance of new shares and consequently there will not be dilution to shareholders.  Full Article

BRIEF-Veloxis Pharmaceuticals raises DKK 4.1 mln from exercise of warrants

* Capital increase from exercise of warrants amounts to 4.1 million Danish crowns ($620,977)